Overview of Delorat

Quick Facts

Property	Description
Active ingredient	Desloratadine (INN)
Form	Oral Tablet, Oral Solution (Syrup)
Pharmacological class	Histamine H1-receptor Antagonist
Common use	Symptomatic relief of allergic discomfort
Origin	Synthetic chemical compound

Classification and Differentiating Features

Delorat is a medication based on the active ingredient Desloratadine, a substance classified as a second-generation antihistamine. This classification places it among the newer class of anti-allergy medicines that are generally non-sedating and exhibit a prolonged duration of action.

Desloratadine is a synthetic compound that is the major active metabolite of the older antihistamine, Loratadine. This makes Desloratadine a more direct compound, which is clinically recognized for its selective action and its low penetration of the blood-brain barrier. The benefit to the patient is an effective anti-allergy treatment that helps maintain alertness.

Formulation and General Purpose

The medication is a single-ingredient product supplied for oral administration, meaning its effects are systemic once swallowed. It is available in various oral dosage forms, including film-coated tablets and a liquid oral solution (syrup). The availability of the syrup form is particularly useful for pediatric patients or those who have difficulty swallowing tablets.

The general purpose of Delorat is to serve as an effective anti-allergy agent. Its mechanism is that of a selective Histamine H1-receptor Antagonist, which means it works by directly blocking the action of histamine, the body’s primary chemical trigger for allergic symptoms. This targeted action helps to control the underlying discomfort associated with allergic responses.

Regulatory References

Antihistamines - StatPearls - NCBI Bookshelf

What side effects are possible with Delorat?

Possible Side Effects and Safety Information

The safety profile of Delorat (Desloratadine) is organized according to standard regulatory classifications, distinguishing between adverse reactions observed commonly in clinical trials and rare, serious events documented through post-marketing surveillance. This structure provides a complete regulatory overview of potential safety outcomes.

Commonly Documented Adverse Reactions

Adverse reactions classified as Common (occurring in 1 to 10 users per 100) and reported more frequently in individuals receiving Desloratadine than placebo in clinical trials include Headache, Dry Mouth, and Fatigue.

System-Organ-Class Safety Groupings

The officially documented adverse effects involve several physiological systems. Key System-Organ Classes affected include Nervous System Disorders (e.g., Headache, Seizures), Gastrointestinal Disorders (e.g., Dry Mouth, Nausea), and Hepatobiliary Disorders (e.g., Hepatitis).

Serious Adverse Reactions and Post-Marketing Events

Very Rare (<1/10,000) but clinically significant events documented primarily through post-marketing reports include severe Hypersensitivity Reactions (such as Anaphylaxis and Angioedema), Hepatitis, and Seizures. Other post-marketing reports with Frequency Not Known include weight gain and increased appetite.

Population-Specific Safety Considerations

Official regulatory documentation notes the need for caution in specific patient populations. Use with caution is indicated for individuals with severe renal impairment due to the drug’s primary excretion route. Similarly, caution is advised for patients with a personal or family history of seizure disorders or in those otherwise predisposed to seizures.

Overdose and Emergency Response

The officially documented descriptions of Delorat overdose indicate that the adverse event profile is similar to the manifestations seen at therapeutic doses, but with a potentially higher magnitude of effects. Common overdose presentations reported in regulatory sources include somnolence, dry mouth, and headache.

Severe outcomes reported in post-marketing surveillance include specific cardiovascular effects such as tachycardia (rapid heart rate) and palpitations. Seizures have also been reported in patients, and QT prolongation was noted in pediatric post-marketing data.

Given these potential risks, immediate medical attention must be sought upon suspicion of overdose. Emergency services (e.g., 911) must be contacted immediately if the affected individual has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened, as required by government guidance.

Management is limited to symptomatic and supportive treatment, including consideration of standard measures to remove unabsorbed substance, as no specific antidote is known. Regulatory documents confirm the drug is not eliminated by hemodialysis. The pediatric population has a noted increased susceptibility to developing new seizures.

Therapeutic Uses of Delorat

What Delorat Treats: Main Uses and Benefits

Delorat is used to provide symptomatic relief for conditions characterized by periods of heightened symptoms, and is commonly used across conditions presenting with acute or recurrent episodes, such as allergic rhinitis (both seasonal hay fever and perennial forms) and urticaria (hives), including the chronic spontaneous type. It is applied to address disruptive symptom clusters like sneezing, runny nose, nasal itching, congestion, and watery eyes, alongside the heightened distress caused by widespread skin itching and wheals.

“The relief of pervasive symptoms contributes to easing the overall symptom load and supports general well-being during symptomatic phases.”

Delorat generally helps support alertness and assists with maintaining functional stability while managing these symptoms, providing supportive relief when symptoms interfere with daily functioning and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Allergic Discomfort

Use Category	Common Conditions	Symptom Focus
Respiratory/ENT	Seasonal and Perennial Rhinitis	Sneezing, nasal itching, congestion, rhinorrhea
Dermatological	Acute and Chronic Urticaria (Hives)	Widespread itching (pruritus), wheals
Functional Benefit	Intermittent and Persistent Symptoms	Sustained alertness, functional stability support

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Delorat (Desloratadine) — Official Regulatory Information

The eligibility profile for Delorat is defined by governmental regulatory documents, outlining who may and may not use the medicine.

Contraindicated Populations

Use of Delorat is absolutely contraindicated in patients with known hypersensitivity to the active substance desloratadine, its parent compound loratadine, or any excipient in the formulation. Furthermore, the tablet form is prohibited for individuals with hereditary problems such as Lapp lactase deficiency or galactose intolerance.

Age-Related and Conditional Restrictions

Population Group	Regulatory Status
Adults & Adolescents (≥12 years)	Approved for tablet use.
Children (<12 years)	Tablet use not recommended; safety and efficacy are not established.
Infants (<6 months)	Use is not established for the oral solution.
Severe Renal/Hepatic Impairment	Use requires caution and may necessitate conditional dosage adjustment.
Pregnancy/Lactation	Not recommended; use is avoided as a precautionary measure due to excretion into breast milk.

Official Eligibility Statements

Use requires caution in patients with a medical or familial history of seizures. The regulatory documents consistently define these restrictions based on patient risk factors, formulation limits, and established safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Delorat (Desloratadine) defines the interaction profile primarily through documented pharmacokinetic alterations and non-interactions. The co-administration of Delorat with specific medicinal products, such as Ketoconazole, Erythromycin, Azithromycin, Cimetidine, and Fluoxetine, results in a pharmacokinetic interaction that increases the plasma concentrations of Desloratadine and its active metabolite. However, regulatory authorities note that no clinically relevant changes in the safety profile were observed in clinical studies involving these combinations.

Interaction Context and Restrictions

Context	Official Regulatory Finding
Timing-based rules	No mandatory requirements for separating the administration time of Delorat from other medicinal products or food are documented in prescribing information.
Food & Grapefruit	Co-administration with food and grapefruit juice is documented as having no effect on the bioavailability or systemic exposure of Desloratadine.
Pharmacodynamic	Clinical trials found that co-administration did not potentiate the performance impairing effects of alcohol.

Population-Specific Exposure Notes

Systemic exposure (AUC) is significantly increased in specific populations due to reduced clearance. This includes patients with severe renal impairment and hepatic impairment, as well as individuals categorized as poor metabolizers of the substance. These conditions result in substantially higher exposure levels compared to the general population, as noted in the official regulatory documentation.

Mechanism of Action

The mechanism of Desloratadine (Delorat) is highly targeted, focusing on the core molecular events that initiate and sustain inflammation in the body. Its action is defined by three key pharmacodynamic domains that transition molecular interactions into predictable physiological effects.

H1 Receptor Inverse Agonism and Pathway Blockade

The drug’s primary mechanism is its action as a selective H1 receptor inverse agonist. By binding to and stabilizing the receptor in an inactive state, the drug functionally blocks the signaling cascade initiated by Histamine. This foundational step reduces the Histamine-driven increase in capillary permeability and the resulting fluid extravasation into peripheral tissues.

️ Modulating Non-Histaminergic Inflammatory Signals

Beyond receptor antagonism, Desloratadine modulates inflammatory cell activity to suppress the release of various pro-inflammatory mediators like certain leukotrienes and cytokines. This influence on the broader inflammatory cascade alters the signaling sequence of secondary inflammation, resulting in modulated physiological activity in the affected tissues.

Strict Peripheral Action

The molecule possesses properties that prevent significant penetration of the Blood-Brain Barrier (BBB), primarily through affinity for the P-glycoprotein efflux pump. This mechanism ensures that H1 receptors in the Central Nervous System (CNS) remain unoccupied, resulting in minimal interference with central histaminergic pathways regulating wakefulness.

Dosage and Administration Information

How to Use Delorat

The general principles for using Delorat are based on its characteristics as a once-daily oral medication for systemic administration, available as a film-coated tablet, an oral solution (syrup), and an orally disintegrating tablet. Administration is standardized, with the medication permitted to be taken without regard to meals.

Standard Dosage and Frequency

The adult and adolescent dose (12 years and older) is standardized at 5 mg once per day. For children, the dose is specific to age, ranging from 1 mg to 2.5 mg once daily depending on the pediatric cohort. The oral solution form is typically used for infants and younger children, requiring measurement with a calibrated device for accurate dosing, rather than a household spoon.

Population-Specific Adjustments

Adjustments are specified for certain adult populations to maintain appropriate systemic exposure. For adults with renal (kidney) or hepatic (liver) impairment, the standard 5 mg dose is initiated every other day (once every two days). No specific dosing recommendations are provided for children with these impairments.

Administration Over Time

The usage pattern over time depends on the nature of the condition being managed. For conditions classified as intermittent, administration can be stopped when symptoms have resolved and reinitiated if symptoms return. In cases where symptoms are persistent, continuous daily administration may be maintained for the duration of allergen exposure.

In the event of a missed dose, the typical approach is to take the dose as soon as remembered, while avoiding taking two doses simultaneously to adhere to the once-daily schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Delorat

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research exploring Delorat’s use for allergic rhinitis, including hay fever, has primarily relied on short-term Randomized Controlled Trials (RCTs) that were placebo-controlled. These clinical trials were applied in studies examining patient-reported outcomes describing perceived discomfort related to sneezing, runny nose, nasal itching, and watery eyes. Researchers also examined outcomes reflecting daily functioning, such as interference with sleep and overall quality of life. The studies included diverse populations, such as Adults and Adolescents, and dedicated research was observed in Children, including infants. In these studies, outcomes measured changes in symptom scores reported across the observed populations, and reports described patterns related to patient-reported sleep quality.

Evidence for Use in Chronic Urticaria (Hives)

Delorat was studied for its use in chronic urticaria (hives)—a condition marked by widespread itching and the appearance of raised welts (wheals). The research relies on Randomized Controlled Trials (RCTs) exploring outcomes related to systemic or functional imbalance. Specifically, studies tracked changes in the number and size of wheals, as well as the intensity of the itching (pruritus). The main studies focused on Adults and Adolescents with active chronic spontaneous urticaria. More recently, research has explored outcomes related to varying dose levels for populations who reported limited change in initial study observations.

Research Gaps and Follow-up Limitations

While core efficacy was explored in short-term trials (lasting only a few weeks), there is limited information for long-term outcomes regarding sustained symptomatic patterns over many months or years. The evidence for long-term effects is not fully established, and certainty remains low for multi-year use. Data for certain groups remain insufficient, such as pregnant or nursing populations. Furthermore, comparative evidence is lacking from extensive head-to-head trials against all newer alternative therapies, meaning most comparisons must be drawn indirectly from analyses pooling multiple studies. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patients observed in the studies.

Frequently Asked Questions (FAQ)

Common questions about Delorat (FAQ)

Q: How is Delorat different from other common medications used for the same condition?

Official information classifies Delorat as a second-generation antihistamine. It is the active metabolite of the older drug Loratadine, which contributes to its specific characteristics. Official information describes its selective action and low penetration of the blood-brain barrier, which studies indicate may have minimal interference with central nervous system functions like wakefulness.

Q: What does the term 'mechanism of action' mean for Delorat?

The mechanism of action describes the specific way the drug works at a molecular level. For Delorat, this mechanism is described as acting on the H1 receptor to block the effects of the body’s primary allergic chemical, histamine, thereby helping to control allergy symptoms.

Q: What happens in the body when Delorat is absorbed?

According to official pharmacokinetics data, the drug reaches its maximum concentration in the blood around three hours after dosing. Official data indicates that the drug begins its antihistaminic effect, as demonstrated in clinical studies, within just one hour.

Q: What does it mean if Delorat is metabolized by liver enzymes?

Metabolism is the process where your body breaks down the drug, primarily in the liver, into its active form, 3-hydroxydesloratadine. This process is important because regulatory documents indicate that if a patient has impaired liver or kidney function, the drug may accumulate, leading to higher levels in the system, and official labeling specifies that this may necessitate a conditional dosage adjustment.

Q: Why does the packaging for Delorat warn against operating heavy machinery?

While studies indicate Delorat is generally non-sedating, common adverse reactions reported in clinical trials include fatigue and general sleepiness. The inclusion of this warning is a standard precaution advised for medications that have reported effects on alertness, such as fatigue and sleepiness.

Q: What specific conditions is Delorat officially approved to treat?

Official regulatory documents state that Delorat is indicated for relieving symptoms associated with Seasonal Allergic Rhinitis (hay fever), Perennial Allergic Rhinitis, and Chronic Idiopathic Urticaria (hives) in patients 12 years of age and older.

Q: How quickly can a person expect to notice the effects of Delorat?

Official information indicates that the drug's antihistaminic effects are demonstrated to start within one hour of administration, based on clinical studies. This represents the time required for the drug to begin its intended action.

Q: How long does the effect of one dose of Delorat last?

Delorat is provided as a once-daily oral medication. Regulatory information states that the antihistaminic effect may persist for as long as 24 hours, which supports this dosing schedule for sustained relief.

Q: Is Delorat safe for older adults to use?

Official information indicates that studies performed on subjects aged 65 years and older found that although drug exposure was slightly higher, these differences were considered not clinically relevant. Regulatory documents note that based on these studies, no specific dosage adjustment is recommended for the elderly population.

Q: Is Delorat available as a generic version?

Yes, official sources confirm that the drug is available under its active ingredient name, Desloratadine. Its marketing status is listed as an Abbreviated New Drug Application (ANDA), which indicates the availability of generic versions.

Q: Is Delorat a controlled substance?

No. Regulatory agencies, such as the Drug Enforcement Administration (DEA), have not classified Delorat as a controlled substance and it is not assigned a DEA schedule.

Q: What is a 'black box warning' and does Delorat have one?

A Black Box Warning (or Boxed Warning) is the strictest warning required by the FDA to call attention to serious or life-threatening risks. According to the official regulatory label, Delorat does not have a Black Box Warning. The label’s most serious warnings focus on precautions against hypersensitivity reactions.

Q: How can I report a side effect from Delorat to the appropriate regulatory body?

The process for reporting suspected adverse reactions is facilitated by the appropriate regulatory authority, such as the FDA through their MedWatch program. Patients can find the contact information provided in the product's patient labeling to submit a report.

Q: Does Delorat cause changes in mood or anxiety levels?

Official post-marketing reports have included instances of nervous system disorders such as psychomotor hyperactivity and, rarely, seizures. The official regulatory text describes these events as requiring caution, and changes in central nervous system function are a noted safety consideration.

How should Delorat be stored and disposed of?

Storage and Disposal of Delorat

Official regulatory documents detail specific conditions required to maintain the stability and safety of Delorat (desloratadine).

Storage Requirement	Conditions as Documented
Temperature Limit	Film-coated tablets must not be stored above 30 C.
Protection Rule	Must be stored in the original package to protect the product from moisture.
Child Safety	Keep out of the sight and reach of children.

Regarding disposal, the product labeling generally states no special requirements for unused medicine or waste materials. This indicates that disposal should follow general regulatory guidelines, such as using an authorized drug take-back program or mixing the product with an undesirable substance for safe disposal in household trash.

Delorat